Healthcare >> CEO Interviews >> November 14, 2011
Daniel P. Gold, Ph.D., was appointed President and Chief Executive Officer of Marshall Edwards, Inc., in April 2010. He joined the company with roughly 25 years of drug discovery and development experience, most recently as President and CEO of Prospect Therapeutics, Inc., a midstage oncology company. Before his tenure at Prospect, Dr. Gold was Founder and Chief Scientific Officer of Favrille, Inc., where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. Dr. Gold's academic qualifications include postdoctoral fellowships at the Dana-Farber Cancer Institute, the Harvard Medical School and The David H. Koch Institute for Integrative Cancer Research at MIT. He holds a doctorate in pathology/immunology from Tufts University and a B.A. in biology from the University of California, Los Angeles. Profile
TWST: Would you begin with an introduction to Marshall Edwards and then give us a description of the business and the organization?
Dr. Gold: Marshall Edwards (MSHL) has its roots as a subsidiary of a
